Heart Failure

No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Findings from SODIUM-HF suggest strategies to reduce dietary sodium intake to less than 1500 mg daily were not more effective than usual care in reducing hospitalization risk.

Findings from VALOR-HCM suggest more data is needed to assess the durability of improvement in septal reduction therapy eligibility over longer time periods.

New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.

Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.

Strategies to improve enrollment of underrepresented populations were centered on study design and site selection, community engagement, and changing the research paradigm.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.

For patients treated with DOACs, the investigators suggest temporarily interrupting treatment rather than continued use.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control.

Patients with tachyarrhythmia or hypertension as their underlying trigger of type 2 MI had a lower mortality than patients with hypotension, hypoxemia, or anemia.

In the most recent episode of Don't Miss a Beat, co-hosts Drs. Vaduganathan and Greene are joined by Dr. Eugene Braunwald for a conversation that touches on the founding of the TIMI Study Group, the evolution of clinical trials, and advice he would give to early career professionals with an interest in becoming trialists.

Levels of troponin after cardiac surgery associated with increased risk of death were higher than levels recommended to define periprocedural myocardial injury.

The heart transplant from a genetically modified pig was initially considered a success and represented new hope for Americans requiring transplants.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.